The company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets.
Gross profit (Q3, 2018)
Gross profit margin (Q3, 2018), %
Net income (Q3, 2018)
EBIT (Q3, 2018)
Market capitalization (12-Feb-2019)
Closing stock price (12-Feb-2019)
VBI Vaccines has 537 Twitter Followers. The number of followers has increased 1.4% month over month and increased 3.2% quarter over quarter
When was VBI Vaccines founded?
VBI Vaccines was founded in 2001.
Who are VBI Vaccines key executives?
VBI Vaccines 's key executives are Jeff Baxter, David E. Anderson and Francisco Diaz-Mitoma.
How many employees does VBI Vaccines have?
VBI Vaccines has 98 employees.
What is VBI Vaccines revenue?
Latest VBI Vaccines annual revenue is $865 k.
What is VBI Vaccines revenue per employee?
Latest VBI Vaccines revenue per employee is $8.8 k.
Who are VBI Vaccines competitors?
Competitors of VBI Vaccines include Sorrento Therapeutics, Pernix Therapeutics and Alnylam Pharmaceuticals.
Where is VBI Vaccines headquarters?
VBI Vaccines headquarters is located at 2241 222 Third St, Cambridge.
Where are VBI Vaccines offices?
VBI Vaccines has offices in Cambridge, Rehovot and Ottawa.
How many offices does VBI Vaccines have?
VBI Vaccines has 3 offices.